CVNA has just reported Q2 results, and the first post-earnings data point worth noting is that the short-covering trend that defined the pre-print period has stalled — and quietly reversed.
Short interest climbed roughly 4% over the past week to 53.1% of free float, ending a multi-week retreat that saw bears trim from peaks above 52% in late June down toward 50% just before the July 29 print. That's now back above those prior peaks — around 75 million shares sold short, per the latest ORTEX estimate, close to the FINRA-reported 76.2 million from mid-July settlement. The reversal is modest in absolute terms but directionally meaningful: the cautious covering that preceded earnings has given way to fresh positioning in the opposite direction. The borrow market, however, remains structurally open. Availability is running near 559%, meaning for every share currently lent out, more than five remain available in the lending pool — well above the 52-week floor of 122%. Cost to borrow ticked up 11% on the week to 0.53% annualised, a slight move but still negligible friction. Options positioning nudged more cautious on Tuesday: the put/call ratio is at 0.88, about one standard deviation above its 20-day average of 0.79, a mild defensive tilt but nowhere near stressed levels.
The Street came into this earnings release already in trim mode. Three analysts — Wells Fargo, Jefferies, and RBC Capital — cut price targets in the weeks preceding the print, while Barclays nudged its target marginally higher to $94. The direction of travel was clearly bearish on estimates, with the consensus mean target now at $89.83 against a close of $66.07, implying roughly 36% upside on paper. That gap deserves context: the bulls cite Carvana's digital platform, GPU expansion capacity, and market-share runway in online auto retail; the bears focus on GPU pressure from recent ABS deals, inventory constraints, and the long-run risk of an ICE-heavy model in an EV transition. Valuation multiples are not cheap — the P/E is running at 38x and EV/EBITDA near 14x, both drifting higher over the past week as the stock moved up. The ORTEX factor score picture reflects that tension: EPS momentum ranks in the bottom decile over both 30 and 90-day windows, while the short-score rank sits at just 15th percentile, flagging that short positioning is extreme relative to peers.
The earnings history adds colour. The prior Q1 print on May 5 delivered a 3.4% next-day gain before a 2.1% five-day drift lower. The Q4 print in late July 2025 produced a 6.4% one-day jump. Neither outcome is catastrophic in either direction, and the actual Q2 release today falls right in line with that pattern — the stock is up 3.2% on the day to $66.07, a controlled reaction rather than a violent squeeze or collapse. The institutional base remains heavyweight: T. Rowe Price holds 12.4% and Capital Research added aggressively last quarter, increasing its position by around 49 million shares to become the second-largest holder at 11.7%. With that level of concentrated long ownership sitting above a 53% short position, the structural tension between the institutional base and the bear camp remains the defining characteristic of this stock.
Insider activity in early July was uniformly sell-side — the CFO, a founder-level executive, and the VP of compliance all sold shares on July 1, though all at low significance scores and in relatively modest size. There is no buy-side insider signal here to complicate the picture.
The week ahead reduces to a single question: whether the post-earnings short rebuild continues or flattens back out. The borrow market has the capacity to absorb substantial new short interest without any squeeze pressure materialising. The next meaningful trigger is whether Q2 results shift analyst consensus enough to close the gap between current targets and the stock's current price.
See the live data behind this article on ORTEX.
Open CVNA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
